PL425406A1 - Zastosowanie mikropęcherzyków pochodzących z komórek macierzystych w leczeniu stanu zapalnego mózgu, zwłaszcza wywołanego udarem - Google Patents

Zastosowanie mikropęcherzyków pochodzących z komórek macierzystych w leczeniu stanu zapalnego mózgu, zwłaszcza wywołanego udarem

Info

Publication number
PL425406A1
PL425406A1 PL42540618A PL42540618A PL425406A1 PL 425406 A1 PL425406 A1 PL 425406A1 PL 42540618 A PL42540618 A PL 42540618A PL 42540618 A PL42540618 A PL 42540618A PL 425406 A1 PL425406 A1 PL 425406A1
Authority
PL
Poland
Prior art keywords
inflammation
brain
stroke
treatment
stem cells
Prior art date
Application number
PL42540618A
Other languages
English (en)
Inventor
Anna Andrzejewska
Sylwia Dąbrowska
Mirosław Janowski
Barbara Łukomska
Original Assignee
Inst Medycyny Doswiadczalnej I Klinicznej Im Miroslawa Mossakowskiego Polskiej Akademii Nauk
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst Medycyny Doswiadczalnej I Klinicznej Im Miroslawa Mossakowskiego Polskiej Akademii Nauk filed Critical Inst Medycyny Doswiadczalnej I Klinicznej Im Miroslawa Mossakowskiego Polskiej Akademii Nauk
Priority to PL42540618A priority Critical patent/PL425406A1/pl
Priority to PCT/PL2019/050027 priority patent/WO2019212371A1/en
Priority to EP19796806.8A priority patent/EP3787648A4/en
Priority to US17/051,892 priority patent/US20210093671A1/en
Publication of PL425406A1 publication Critical patent/PL425406A1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Przedmiotem zgłoszenia są mikropęcherzyki pochodzące z mezenchymalnych komórek macierzystych do stosowania jako lek immunomodulujący podawany dotętniczo w leczeniu stanu zapalnego mózgu, zwłaszcza wywołanego udarem. Przedmiotem zgłoszenia jest też kompozycja farmaceutyczna do leczenia stanu zapalnego mózgu, zwłaszcza wywołanego udarem, charakteryzująca się tym, że zawiera mikropęcherzyki pochodzące z komórek macierzystych, przy czym kompozycja jest przeznaczona do podawania dotętniczego.
PL42540618A 2018-04-30 2018-04-30 Zastosowanie mikropęcherzyków pochodzących z komórek macierzystych w leczeniu stanu zapalnego mózgu, zwłaszcza wywołanego udarem PL425406A1 (pl)

Priority Applications (4)

Application Number Priority Date Filing Date Title
PL42540618A PL425406A1 (pl) 2018-04-30 2018-04-30 Zastosowanie mikropęcherzyków pochodzących z komórek macierzystych w leczeniu stanu zapalnego mózgu, zwłaszcza wywołanego udarem
PCT/PL2019/050027 WO2019212371A1 (en) 2018-04-30 2019-04-30 Use of microvesicles derived from stem cells in treatment of neuroinflammation, particularly induced by stroke
EP19796806.8A EP3787648A4 (en) 2018-04-30 2019-04-30 USE OF MICROVEESICLES FROM STEM CELLS IN THE TREATMENT OF NEURO-INFLAMMATION, ESPECIALLY INDUCED BY A CEREBRAL VASCULAR ACCIDENT
US17/051,892 US20210093671A1 (en) 2018-04-30 2019-04-30 Use of microvesicles derived from stem cells in treatment of neuroinflammation, particularly induced by stroke

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL42540618A PL425406A1 (pl) 2018-04-30 2018-04-30 Zastosowanie mikropęcherzyków pochodzących z komórek macierzystych w leczeniu stanu zapalnego mózgu, zwłaszcza wywołanego udarem

Publications (1)

Publication Number Publication Date
PL425406A1 true PL425406A1 (pl) 2019-11-04

Family

ID=68385977

Family Applications (1)

Application Number Title Priority Date Filing Date
PL42540618A PL425406A1 (pl) 2018-04-30 2018-04-30 Zastosowanie mikropęcherzyków pochodzących z komórek macierzystych w leczeniu stanu zapalnego mózgu, zwłaszcza wywołanego udarem

Country Status (4)

Country Link
US (1) US20210093671A1 (pl)
EP (1) EP3787648A4 (pl)
PL (1) PL425406A1 (pl)
WO (1) WO2019212371A1 (pl)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2603592A2 (en) * 2010-08-13 2013-06-19 The University Court of the University of Glasgow Therapeutic uses of microvesicles and related micrornas
US11692172B2 (en) * 2017-06-26 2023-07-04 Mackay Memorial Hosptal Formulation comprising extracellular vesicles, method for producing the same, and uses thereof

Also Published As

Publication number Publication date
EP3787648A1 (en) 2021-03-10
US20210093671A1 (en) 2021-04-01
WO2019212371A1 (en) 2019-11-07
EP3787648A4 (en) 2021-08-25

Similar Documents

Publication Publication Date Title
PH12020551716A1 (en) Anti-ror antibody constructs
GEP20217252B (en) Highly concentrated low viscosity masp-2 inhibitory antibody formulations, kits, and methods
PH12020551043A1 (en) Compounds, compositions, and methods for treatment of diseases involving acidic or hypoxic diseased tissues
EA201692177A1 (ru) Соединения и композиции в качестве агонистов toll-подобного рецептора 7
MX2019014041A (es) Inhibidores pirazolicos de magl.
EA201890725A1 (ru) Агонисты фарнезоидного х-рецептора и их применение
EA201692201A1 (ru) Соединения и композиции в качестве агонистов toll-подобного рецептора 7
MY196909A (en) Boronic acid derivatives and therapeutic uses thereof
EP4628094A3 (en) BAFF-R ANTIBODIES AND THEIR USES
EA201591403A1 (ru) Спиролактамные модуляторы рецептора nmda и их применение
EA201991447A1 (ru) Снижение вязкости фармацевтических составов
WO2018067520A3 (en) Therapeutic agents and methods:
MX2020011100A (es) Compuestos, composiciones farmaceuticas y metodos de uso de agonistas de ppar.
MX2017000764A (es) Formulacion acuosa que comprende paracetamol e ibuprofeno.
EA201891609A1 (ru) Производные 3-((гетеро-)арил)алкил-8-амино-2-оксо-1,3-диазаспиро[4.5]декана
CR20190536A (es) Inhibidores pirazólicos de magl
EA201891610A1 (ru) Производные 3-(карбоксиэтил)-8-амино-2-оксо-1,3-диазаспиро[4.5]декана
CR20220322A (es) Formulaciones de anticuerpos anti-pd-l1
EA201792571A1 (ru) Терапевтическое применение l-4-хлорокинуренина
GEAP201814255A (en) P-substituted asymmetric ureas and medical uses thereof
EA201591717A1 (ru) Твердые формы гидрохлорида вемурафениба
MX2017006513A (es) Compuestos de tipo 1,9-diazaespiroundecano con actividad multimodal contra el dolor.
MX2021010207A (es) Formulacion farmaceutica de liberacion extendida.
CL2016002321A1 (es) Compuestos derivados del ácido 2-8-5-cloropirimidin-2-ilamino-6,7,8,9-tetrahidro-5h-pirido3,2-bindol-5-ilacético, moduladores del receptor de prostaglandina d2 composición farmacéutica y su uso para el tratamiento de enfermedadestrastornos alérgicosinmunitarios.
CO2018011420A2 (es) Formulaciones líquidas de fosfaplatino